Add to watchlist
€0.008
Last updated:06/11/2021
0LW: F
Neovacs S.A

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid techno… Show more

P/E ratio
-
vs. 0.00x forward

Company has negative earnings per share so P/E ratio is not available.

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2016
2017
2018
2019
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-13.932463M
-14.83844M
-6.50%
-10.780484M
+27.35%
-7.548215M
+29.98%
Cashflow
Sum up money going in and out company
-10.996887M
-14.256844M
-29.64%
-13.305716M
+6.67%
-8.099508M
+39.13%
Total liabilities
All combined debts and obligations
8.078088M
10.826499M
+34.02%
4.801761M
-55.65%
4.799284M
-0.05%
Company profile
CEO
Mr. Hugo Brugiere
Market capitalization
Nano (17.19M)